Lantern Pharma Inc. LTRN
We take great care to ensure that the data presented and summarized in this overview for Lantern Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LTRN
View all-
Bios Capital Management, LP Fort Worth, TX1.21MShares$5.91 Million4.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$1.78 Million0.0% of portfolio
-
Cm Management, LLC200KShares$977,9990.6% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny87.3KShares$426,8970.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87KShares$425,2970.0% of portfolio
-
New Edge Advisors, LLC New Orleans, LA68.4KShares$334,2750.0% of portfolio
-
Voss Capital, LLC Houston, TX50KShares$244,4990.01% of portfolio
-
Black Rock Inc. New York, NY39.8KShares$194,8220.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il37.6KShares$183,8000.0% of portfolio
-
Redmond Asset Management, LLC Henrico, VA37.3KShares$182,2500.03% of portfolio
Latest Institutional Activity in LTRN
Top Purchases
Top Sells
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Insider Transactions at LTRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 24
2024
|
D Jeffrey Keyser Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
3,832
+100.0%
|
$11,496
$3.13 P/Share
|
|
May 24
2024
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-3.13%
|
$120,000
$6.33 P/Share
|
|
May 24
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-3.13%
|
$120,000
$6.33 P/Share
|
|
May 23
2024
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-1.54%
|
$60,000
$6.25 P/Share
|
|
May 23
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-1.54%
|
$60,000
$6.25 P/Share
|
|
Feb 29
2024
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,703
-2.95%
|
$78,812
$4.87 P/Share
|
|
Feb 29
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,703
-2.95%
|
$78,812
$4.87 P/Share
|
|
Feb 28
2024
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
74,297
-10.01%
|
$297,188
$4.85 P/Share
|
|
Feb 28
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
74,297
-10.01%
|
$297,188
$4.85 P/Share
|
|
Feb 27
2024
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
50,000
-6.31%
|
$200,000
$4.4 P/Share
|
|
Feb 27
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
50,000
-6.31%
|
$200,000
$4.4 P/Share
|
|
Jan 17
2024
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
58,889
-6.92%
|
$235,556
$4.2 P/Share
|
|
Jan 17
2024
|
Leslie W. Kreis > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
79,021
+8.5%
|
$237,063
$3.13 P/Share
|
|
Jan 17
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
58,889
-6.92%
|
$235,556
$4.2 P/Share
|
|
Jan 17
2024
|
Aaron G.L. Fletcher > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
79,021
+8.5%
|
$237,063
$3.13 P/Share
|
|
Nov 29
2023
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
145,348
-19.78%
|
$436,044
$3.44 P/Share
|
|
Nov 29
2023
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
145,348
-19.78%
|
$436,044
$3.44 P/Share
|
|
Nov 08
2022
|
Aaron G.L. Fletcher > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
350,000
-19.01%
|
$1,400,000
$4.4 P/Share
|
|
Nov 08
2022
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
350,000
-19.01%
|
$1,400,000
$4.4 P/Share
|
|
Sep 02
2022
|
Leslie W. Kreis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,445
-12.23%
|
$32,225
$5.2 P/Share
|
Last 12 Months Summary
| Exercise of in-the-money or at-the-money derivatives securities | 3.83K shares |
|---|
| Open market or private sale | 348K shares |
|---|